DARPA BTO - A Commercial Multiplier for Bio & DeepTech

​Please join NFX and SRI for a special lunch time session welcoming the DARPA Biotechnology Office (BTO) to JPM week. Featuring an update on new office priorities from BTO Director Dr. Michael Koeris, a discussion of DARPA commercialization strategy, how VCs can work with DARPA, and a fast-pitch session with four startups commercializing BTO-funded technology, attendees will get an overview of how BTO is not only engaged in the funding of cutting edge science, but supporting commercial transition to industry.

​ 

​About the hosts:

• ​NFX is a Seed Stage VC with $1.4B under management.
  
  NFX Bio is the home for Scientist-Founders. We have been in your shoes, and have, ourselves, invented new approaches to biology and started and scaled these companies to multi-billion dollar outcomes. We operate with a very different value system:

  • ​We make fast decisions

  • ​We understand the science and the business

  • ​We prefer to lead rounds

​

• ​SRI is an independent, nonprofit research institute, with a deep legacy of world-changing technology innovation, and a mandate to transition research advances to the market.
  
  Collaborating broadly with scientists, industry, startups, and the federal government, SRI has multiple mechanisms to advance innovation to the market.

  • ​The SRI Biosciences Division actively supports pharma through both the pre-clinical and clinical research and development, as well as supports an active pipeline of cutting-edge proprietary biotechnology platforms and compounds.

  • ​SRI Ventures partners with entrepreneurs at the earliest stages to build category-defining deep technology companies such as Siri, Intuitive Surgical, and LeoLabs.

  • ​SRI also directly supports federal innovation priorities as a DARPA Regional Commercial Accelerator.

​ 

​Logistics:

• ​Lunch to be provided.

• ​Venue capacity is limited, so please reach out to your friends at NFX or SRI if you have any issues with registration.